Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 trial of inhaled MK-5475 in adults with pulmonary arterial hypertension
MOH_2021-04-26_009585Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of frespaciguat in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Merck & Co. Primary endpoint: Efficacy of MK-5475 versus placebo. Started Feb 2021; status: recruiting.
02
Drugs
frespaciguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2021-04-26_009585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-26_009585.